MGMT and central nervous system cancer: By integrating SC2I, age, gender, MGMT promoter status, IDH mutation status, WHO grade, and original subtype, we established a nomogram to accurately predict the 1-, 2- and 3-year survival probability of glioma patients (Figure 5A).